Anemia in heart failure: pathophysiologic insights and treatment options (Q37445907)

20 August 2017

1 reference

title

Anemia in heart failure: pathophysiologic insights and treatment options (English)

1 reference

20 August 2017

0 references

1 reference

John V Terrovitis

1

1 reference

20 August 2017

Maria Anastasiou-Nana

2

1 reference

20 August 2017

Elissavet Kaldara

3

1 reference

20 August 2017

Stavros G Drakos

4

1 reference

20 August 2017

Serafeim N Nanas

5

1 reference

20 August 2017

John N Nanas

6

1 reference

20 August 2017

language of work or name

1 reference

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

71-81

1 reference

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia and its relationship to clinical outcome in heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia and heart failure: a community study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia and mortality in heart failure patients a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Relation of anemia to diastolic heart failure and the effect on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Are hematinic deficiencies the cause of anemia in chronic heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia and chronic heart failure implications and treatment options.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Heart failure and anemia: mechanisms and pathophysiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Etiology of anemia in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia of chronic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

The association between congestive heart failure and chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Effect of anemia on exercise tolerance in chronic heart failure in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Erythropoietin and systemic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Effects of treatment with epoetin beta on outcomes in patients with anaemia and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Protective effects of erythropoietin in cardiac ischemia: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Intravenous iron supplementation in the anaemia of renal and cardiac failure--a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Parenteral iron therapy exacerbates experimental sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Labile iron in parenteral iron formulations: a quantitative and comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Recent advances in erythropoietic agents in renal anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

Canadian Randomized Trial of Hemoglobin Maintenance to Prevent or Delay Left Ventricular Mass Growth in Patients With CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.1.71

21 January 2018

Identifiers

DOI

10.2217/14796678.5.1.71

1 reference

20 August 2017

1 reference